



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

**Summary of Main Points from the Meeting held on
Monday 16th June 2025**

2. Minutes and Summary Notes from last meeting

This meeting was held via Teams. The Minutes and Summary notes of the Medicines Group Meeting held on 10th February 2025 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

- Nil

Short Applications

- **Ciclosporin (Cequa[®]) 0.9mg/ml Eye Drops**

Requested by: Ophthalmology

Clinical Indication: Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes

Proposal: Add to the formulary as an alternative option to Ciclosporin (Ikervis[®]) (1mg/ml)

New formulation with a nanomicellar aqueous formulation that claims to have enhanced drug solubility and ocular tissue availability.

For patients who do not tolerate Ikervis[®] (1mg/ml formulation) or required BD dosing of Ikervis[®] (off-label).

Cost implication: Cequa[®] £77.76 vs Ikervis[®] £86.40 for 30 day treatment

Outcome: Approved for addition to the Trust Formulary

- **Triamcinolone Acetonide (Intracinol[®]) 40mg/ml Injection**

Requested by: Ophthalmology

Clinical indication: Management of uveitis/eye infection

Visualisation during ophthalmic procedures.

Proposal: Add to the formulary as an alternative to Triamcinolone injection 40mg/ml which has been discontinued.

Is licensed as a medical device for ophthalmic use.

This formulation will only be used for ophthalmic indications.

Cost implication: Discontinued Triamcinolone injection 40mg/ml - £1.6 per unit

Triamcinolone Ophthalmic Injection (Intracinol[®]) - £94.8 per unit

Outcome: Approved for addition to the Trust Formulary

NICE TA Applications

- **TA1036 Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (05/02/2025)**

Proposal: Add to the formulary in line with NICE TA1036

Outcome: Approved for addition to the Trust Formulary

- **TA1063 Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment (15/05/2025)**



Proposal: Add to the formulary in line with NICE TA1063

Outcome: Approved for addition to the Trust Formulary

NWL ICB JFC Applications

- **Pylera® (140 mg of Bismuth Subcitrate Potassium, 125mg Metronidazole and 125 mg Tetracycline Hydrochloride)**

Proposal: Add to the Trust formulary in line with NWL ICB JFC decision Helicobacter Pylori eradication therapy (in line with local antimicrobial guidance)

Outcome: Approved for addition to the Trust Formulary

- **Doxylamine 10mg / Pyridoxine 10mg Tablets (Xonvea®)**

Proposal: Add both to the Trust formulary in line with NWL ICB JFC decision - Management of moderate to severe nausea and vomiting in pregnancy after trialling of at least two regular antiemetics.

Outcome: Approved for addition to the Trust Formulary

Pharmacoeconomic Board Applications

- **Cemiplimab for Basosquamous Carcinoma**

Approved by Pharmacoeconomic Board on 26/02/2025 - For noting

Outcome: Noted

- **Oxandrolone for Burns**

Approved by Pharmacoeconomic Board on 24/03/2025 - For noting

Outcome: Noted

- **Venetoclax for Myelodysplasia**

Approved by Pharmacoeconomic Board on 20/03/20245 - For noting

Outcome: Noted

- **Injectable ARVs (Lenacapavir, Cabotegravir, Rilpivirine) for HIV**

Approved by Pharmacoeconomic Board on 30/04/2025 - For noting

Outcome: Noted

- **Etanercept for TEN**

Approved by Pharmacoeconomic Board on 30/05/2025 - For noting

Outcome: Noted

- **Vedolizumab for Paediatric IBD**

Approved by Pharmacoeconomic Board on 27/05/2025 - For noting

Outcome: Noted

Removals

- **Antazline 0.5% / Xylometazoline 0.05% Eye Drops (Otrivine-Antistin®)**

Proposal: Remove from the formulary. Discontinued by the manufacturer

Outcome: Approved for removal from the Trust Formulary

Other

Early Access Scheme: Pritelivir 100mg Tablets unit dose for the management of Herpes Simplex Infection

Proposal: Approve scheme on account of unmet clinical need

Outcome: EAS approved for use in the Trust

4.2 Trust Medicines Policy

- **TMG: Section 4 - Storage of medicines**

Routine review and update.



Addition of:

- RPSGB standards in an audit form in Appendix 4.6
- Statement: If a drug storage space used for the storage of medicines is labelled, an A-Z labelling system should be used in preference to using specific medicine names.
- Statement: Patient's own medicines that have been left on the hospital premises cannot be returned into Pharmacy/ward stock and/or reused irrespective of storage and/or expiry date and must be discarded.
- Need to store intravenous fluids and frequently used small volume injections presented in vials/ampoules in their original packaging, not loose, or decanted unless there is a risk assessment in place.
- Additional section relating to insulin: Annotation of expiry date on insulin vials once opened; Labelling of pre-filled insulin pens with patient's name and expiry date.
- Annotation of medicines that have limited shelf life on opening with the allocated expiry date once opened.
- Clarity that temperature reading should be taken *at least once* every 24 hours.
- Action to take relating to temperature monitoring if a clinical area is temporary closed.
- Statement: There is a minimum of one ambient thermometer in place on the ward/department which is located in the Treatment Room, if there is one present, or in the area where the majority of the stock medicines are stored.
- Use of an electronic solution (e.g. FDP) to record ambient temperatures.
- Safe and secure storage of medicines on wards/departments Audit Form in Appendix 4.7.
- Section relating to the storage of flammable medicines.
- Section relating to the procurement of thermometers

Update of:

- Appendix 4.1

Noting of subsequent changes following TMG February 2025

Outcome: Approved

- **TMP: Section 8 - Administration of medicines**

Routine review and update:

- Update: List of medicines that can be administered by Nursing Associates
- Update: Tramadol, Pregabalin and Gabapentin do not require double-checking of administration
- Update: Wording on Stock Liquid Medicine sticker
- Update: Second check required for all medicines administered via the following routes: Intrathecal, Intra-arterial, Intraventricular, Epidural, Intravesicular, Intravitreal, Intrapleural and Intraocular

Outcome: Approved

- **TMP Section 17. Injectable Medicines Policy**

Updated in tandem to reflect the update to Section 8: List of medicines that can be administered by Nursing Associates

Outcome: Approved

- **TMP: Section 10 - Admissions and Discharge**

Addition of a new section re. Deprescribing (Section 10.2)

Outcome: Approved

- **TMP: Section 14 - Reporting Adverse Drug Reactions and Clinical Incidents**

Routine review and update including:

- Update to related Trust policies
- Revision of definition of an ADR
- Update on what to report, how to report, information to report, benefits to reporting and outcome after report submission
- Need to complete a Trust incident report on Datix relating to any medicines-related incident identified as being suspected of causing moderate harm. Level of harm to be agreed with the responsible consultant.



- Removal of information relating to Commercial Medicines Unit
- Update to policies and references cited

Outcome: Approved

- **TMP: Section 24 - Concentrated Potassium Solutions**

Removal of Startlight Ward from the list of wards/department that stock Potassium Chloride 15% (1.5g in 10ml) ampoules/vials at WMUH.

Outcome: Approved

- **TMP: Section 26 - Critical list of omitted and delayed medicines**

Routine review and update:

- Update to references within policy
- Inclusion of clozapine to the List of Critical Medicines

Outcome: Approved

- **TMP: Section 28 - Controlled Drugs Governance Arrangements**

Routine review and update

Addition:

- Note that the Chief Pharmacist currently assumes the role of Trust Accountable Officer for Controlled Drugs.
- A list of CD incident types that are routinely escalated to NHS England.
- Archiving of reports

Update:

- Controlled Drugs (Supervision of Management and Use) Regulations 2006 - Updated to 2013
- E-mail address for Trust CDAO
- The named Metropolitan Police London Region Liaison Officer for Controlled Drugs and contact details
- CCG - Updated to ICB
- Appendices

Outcome: Approved

- **TMP: Section: 33 - Pharmacy Service outside regular working hours**

Routine review and update

- Change in out-patient outsourced service from Boots to CW Medicines
- Update to the opening times of CW Medicines
- Update to the opening times for WMUH Pharmacy
- Update to the locations of the ward/department stock lists on the Trust Intranet
- Additional option added for wards/departments to borrow stock medicines out-of-hours at CWH Site.
- Update to Appendices

Outcome: Approved

- **TMP: Section 36 - Handling and administration of monoclonal antibody products**

New section drafted and approved by Chair TMG - For noting

Outcome: Approved

- **TMP: Section 37 - Equality Impact Assessment**

Routine review and update

Outcome: Approved

- **TMP Audit 2025 - Plan**

Plan for Trust Medicines Policy Audit 2025

Outcome: Approved



4.3 Medicines Optimisation

- **Guideline for pharmacy and medical staff managing patient on Clozapine (CWH Site)**

Currently two separate guidelines exist. The current version of guideline for the CWH site has expired.

Only changes on this reviewing include:

- Contact details for the CNWL Mental Health Pharmacist

Plan is for the two guidelines to be merged to streamline the process and discussions between the two teams has already started to progress this.

Outcome: Approved

- **Poster re. How to manage patients on Lithium**

Poster drafted to support the management of patients receiving Lithium (Trust guideline was approved by TMG in April 2024).

This poster has been retrospectively added to the Trust policy as an appendix.

Outcome: Approved

- **North West London ICS response to valproate National Patient Safety Alerts - Summary Report**

Report that summarise the challenges and the results of all the work undertaken across the NWL ICS in response to the valproate National Patient Safety Alerts which aims to improve valproate safety and reduce the risk to unborn children.

The report was taken to the System Quality Group (oversight group for the Alert) and to IMOC. It was agreed to step-down the ICS Valproate Integrated Quality Improvement (VIQI) Task and Finish Group and the ICS is now formally transfer governance for oversight of completion of valproate action plans to the internal Provider Trust governance systems.

Outcome: Noted

- **Annual Medication Safety Report 2024-25**

Annual Medication Safety Report for 2024-25

Outcome: Noted

- **NW London ICB Integrated Medicines Optimisation Committee**

Summary of prescribing efficiencies that have been proposed for NWL ICB for 2024/25

Outcome: Noted

- **NWL ICB Joint Formulary Committee Updates**

Update from the NWL ICB Joint Formulary Committee

Outcome: Noted

4.4 NICE Technical Appraisals and Guidance

38 TA appraisals published since previous TMG meeting to June 2025

- **TA1028 Bimekizumab for treating moderate to severe hidradenitis suppurativa (15/01/2025)**

Formulary status / Action

Nil - Terminated Appraisal

- **TA1029 Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (15/01/2025)**

Formulary status / Action

Nil - Terminated Appraisal

- **TA1030 Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (15/01/2025)**

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: 2 patients per year

Numbers likely to treat at WIMUH site: 2 patients per year



- **TA1031 Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over (16/01/2025)**
Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site
- **TA1032 Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (22/01/2025)**
Formulary status / Action
Nil - Terminated Appraisal
- **TA1033 Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (12/02/2025)**
Formulary status / Action
Nil - Not recommended
- **TA1034 Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (22/01/2025)**
Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site
- **TA1035 Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (23/01/2025)**
Formulary status/Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site
- **TA1036 Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (05/02/2025)**
Formulary status/Action
Not included on the formulary
Application form received - See Section 4.1
- **TA1037 Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (05/02/2025)**
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 1 patient per year
Numbers likely to treat at WMUH site: 1 patient per year
- **TA1038 Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over (12/02/2025)**
Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site
- **TA1039 Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (12/02/2025)**
Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site
- **TA1040 Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (12/02/2025)**
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: N/A
Numbers likely to treat at WMUH site: 2-4 patients per year



- **TA1041 Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (19/02/2025)**
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 1 patient per year
Numbers likely to treat at WMUH site: 1 patient per year
- **TA1042 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (19/02/2025)**
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 1 patient per year
Numbers likely to treat at WMUH site: 1 patient per year
- **TA1043 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (26/02/2025)**
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 1 patient per year
Numbers likely to treat at WMUH site: 2 patients per year
- **TA1044 Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (26/02/2025)**
Formulary status/Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site
- **TA1045 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (05/03/2025)**
Formulary status/Action
Not included on the formulary
Action: Awaiting confirmation from ICB if it will be applicable. If so, add to the formulary following receipt of an application form from the ENT Department.
- **TA1046 Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (12/03/2025)**
Formulary status / Action
Nil - Not recommended
- **TA1047 Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (12/03/2025)**
Formulary status / Action
Nil - Terminated Appraisal
- **TA1048 Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (26/03/25)**
Formulary status/Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site
- **TA1049 Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia (26/03/2025)**
Formulary status/Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site



- **TA1050 Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (26/03/2025)**
Formulary status/Action
Not included on the formulary
Action: Not applicable to CWFT - Not a commissioned site
- **TA1051 Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (02/04/2025)**
Formulary status/Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site
- **TA1052 Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (02/04/2025)**
Formulary status / Action
Nil - Terminated Appraisal
- **TA1053 Cladribine for treating active relapsing forms of multiple sclerosis (15/04/2025)**
Formulary status / Action
Not included on the formulary
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: ___ patients per year
Numbers likely to treat at WMUH site: ___ patients per year
- **TA1054 Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (15/04/2025)**
Formulary status / Action
Included on the formulary for another indication
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site
- **TA1055 Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (16/04/2025)**
Formulary status / Action
Included on the formulary for another indication
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site
- **TA1056 Molnupiravir for treating COVID-19 (16/04/2025)**
Formulary status / Action
Included on the formulary already for same indication
- **TA1057 Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (16/04/2025)**
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 100 patients per year
Numbers likely to treat at WMUH site: 70-80 patients per year
- **TA1058 Tislelizumab in combination for untreated advanced non-small-cell lung cancer (23/04/2025)**
Formulary status / Action
Nil - Terminated Appraisal
- **TA1059 Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (07/05/2025)**
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 5-10 patients per year
Numbers likely to treat at WMUH site: 5-10 patients per year



- **TA1060 Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer (08/05/2025)**

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: 3 - 4 patients per year

Numbers likely to treat at WMUH site: 0 patients per year (Likely to treat 3-4 patients per year when Ambulatory Diagnostic Centre is open - Due to open in October 2027)

- **TA1061 Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (06/05/2025)**

Formulary status / Action

Nil - Terminated Appraisal

- **TA1062 Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (12/05/2025)**

Formulary status/Action

Not included on the formulary

Action: Add to the formulary following receipt of an application form from the Oncology Department or N/A?

- **TA1063 Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment (15/05/2025)**

Formulary status/Action

Not included on the formulary

Application form received - See Section 4.1

- **TA1064 Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (22/05/2025)**

Formulary status / Action

Included on the formulary for another indication

Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site

- **TA1065 Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (28/05/2025)**

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: 8 patients per year

Numbers likely to treat at WMUH site: 2 patients per year

b) NICE Highly Specialised Technology Appraisals published since last meeting

2 HST appraisal published since previous TMG meeting to May 2025

- **HST32 - Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B (02/04/2025)**

Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site

- **HST33 - Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (23/04/2025)**

Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site

c) NICE TA Summary for 2024/25

Summary of Trust status re. NICE TAs published between 01/04/2024 to 30/03/2025

Outcome: Noted



d) NICE HST Summary for 2024/25

Summary of Trust status re. NICE HSTs published between 01/04/2024 to 30/03/2025

Outcome: Noted

4.5 Items for noting

• **Quarterly Controlled Drug Summary Report - Q3 2024/25**

Quarterly Controlled Drug Summary Report for Q3 2024/25

Outcome: Noted

• **Quarterly Controlled Drugs Accountable Officer Report - Q3 2024/25**

Quarterly CD Accountable Officer Report for Q3 2024/25

Outcome: Noted

• **Medication Safety Bulletin: Look alike sound alike medicines**

Medication Safety Bulletin relating to Look alike sound alike medicines

Outcome: Noted

• **Medication Safety Bulletin: Clozapine**

Medication Safety Bulletin relating to Clozapine

Outcome: Noted

• **Medication Safety Bulletin: Unfractionated Heparin**

Medication Safety Bulletin relating to Unfractionated Heparin

Outcome: Noted

• **Medication Safety Bulletin: Therapeutic Drug Monitoring**

Medication Safety Bulletin relating to Therapeutic Drug Monitoring

Outcome: Noted

• **MHRA Drug Safety Update - February 2025**

MHRA update for February 2025

Outcome: Noted

• **MHRA Drug Safety Round-up - March 2025**

MHRA round-up for March 2025

Outcome: Noted

• **MHRA Drug Safety Round-up - April 2025**

MHRA round-up for April 2025

Outcome: Noted

• **MHRA Drug Safety Round-up - May 2025**

MHRA round-up for May 2025

Outcome: Noted

4.6 Meeting minutes for noting

• **Trust Medicines Group Terms of Reference - June 2025**

Trust Medicines Group - Terms of Reference - June 2025

Outcome: Noted

• **NWL ICB Joint Formulary Committee Meeting Minutes - January 2025**

Minutes from NWL ICB Joint Formulary Committee Meeting held January 2025

Outcome: Noted



- **NWL ICB Joint Formulary Committee Meeting Minutes - March 2025**

Minutes from NWL ICB Joint Formulary Committee Meeting held March 2025

Outcome: Noted

- **Antibiotic Steering Group Meeting Minutes - January 2025**

Minutes from Antibiotic Steering Group Meeting held January 2025

Outcome: Noted

- **Medicines Optimisation Steering Group Action Log - April 2025**

Action Log from Medicines Optimisation Steering Group held April 2025

Outcome: Noted

- **Medication Safety Group meeting minutes - February 2025**

Minutes from Medication Safety Group Meeting held February 2025

Outcome: Noted

- **Medication Safety Group meeting minutes - April 2025**

Minutes from Medication Safety Group Meeting held April 2025

Outcome: Noted

5. Any other business

- **Trust Medicines Policy: Section 22 - Non-Medical Prescribing: Expiry date extended by 6 months**

Trust Medicines Policy: Section 22 - Non-Medical Prescribing: Expiry date has been extended by 6 months via Chair's Action with approval from Chief Pharmacist

Outcome: Noted

- **Trust Non-Medical Prescribing Lead has been appointed**

New Trust Non-Medical Prescribing Lead has been appointed.

Outcome: Noted

6. Date of next meeting

Meetings Dates for 2025

Date:

- **29th September 2025**
- **24th November 2025**

Time: 8am-9am

Location: via Teams